Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue suppl 10, Pages x53-x58
Publisher
Oxford University Press (OUP)
Online
2013-11-21
DOI
10.1093/annonc/mdt472
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
- (2013) Dan Stark et al. LANCET ONCOLOGY
- Latest research and treatment of advanced-stage epithelial ovarian cancer
- (2013) Robert L. Coleman et al. Nature Reviews Clinical Oncology
- How to approach patients in relapse
- (2012) E. Pujade-Lauraine ANNALS OF ONCOLOGY
- Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
- (2012) Bradley J. Monk et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
- (2012) Georgia A. McCann et al. GYNECOLOGIC ONCOLOGY
- Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study
- (2012) Dana M. Chase et al. GYNECOLOGIC ONCOLOGY
- Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study
- (2012) Bradley J. Monk et al. GYNECOLOGIC ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF Inhibition, Hypertension, and Renal Toxicity
- (2012) Suzanne R. Hayman et al. Current Oncology Reports
- At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
- (2011) David E. Cohn et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
- (2010) Ernest S. Han et al. GYNECOLOGIC ONCOLOGY
- Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
- (2008) S. Mabuchi et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now